Extensive Phase 3 programme demonstrates clinical potential of BAREMSIS in rescue treatment and prophylaxis of PONV – NDA to be submitted to the US FDA 1H 2017
Cambridge, UK – 13th February 2017
Acacia Pharma Group Ltd (“Acacia Pharma”), the supportive care company developing products for US and international markets, announces positive results from its fourth and final pivotal Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) for the rescue treatment of patients who develop post-operative nausea & vomiting (PONV), despite having received prior antiemetic prophylaxis.
Please click here to read the full press release from Acacia.
February 16, 2017
Company Named Finalist for PACT Technology Company of the Year Award
ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, today announced it has been named a finalist for the Philadelphia Alliance for Capital and Technologies (PACT) Technology Company of the Year Award. ERT is one of only three companies nominated to receive this recognition.
Click here to read ERT's news release.
15 February 2017
London, UK: BTG plc (LSE: BTG), the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology.
Click here to read BTG's press release.
Please see here for more information.
Click here to read Lysogene's press release.
Hoersholm, 2017-02-01 15:43 CET (GLOBE NEWSWIRE) --
Click here to read Chr. Hansen's company announcement no. 4/2017.
$960 million deal will enhance Lilly’s existing pain management portfolio for migraine; adds potential near-term launch to its late-stage pipeline
INDIANAPOLIS, IN and CAMBRIDGE, MA, January 18, 2017–
Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) today announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly’s existing portfolio in pain management for migraine, while adding a potential near-term launch to its late-stage pipeline.
Click here to read CoLucid's news release.
Chr. Hansen has had a good start to the year with strong organic revenue growth of 11% in Q1 2016/17, which is better than initially expected for the quarter. Revenue reached EUR 242 million – 13% above last year.
Click here to read the full press release.
10 January 2017
BTG plc (LSE: BTG), the global specialist healthcare company, today announced the first patients diagnosed with Pulmonary Embolism (PE) to be treated in Hong Kong using the newly available EKOS® system. The EKOS® system includes an ultrasonic device that uses acoustic pulses to quickly and safely dissolve blood clots and restore blood flow in patients with PE, deep vein thrombosis (DVT), and peripheral arterial occlusions (PAO).
Click here to read the full news release from BTG.
LAUSANNE, Switzerland, and CAMBRIDGE, MA January 9, 2017
Anokion, a privately held biopharmaceutical company developing novel tolerance-inducing therapeutics for autoimmune diseases, today announced the formation of an exclusive global research collaboration with Celgene Switzerland LLC, an affiliate of Celgene Corp.
Click here to read the full news release from Anokion.
Tubingen (Germany), January 05, 2017
HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today the completion of a €9 million Series A financing. The round was led by Boehringer Ingelheim Venture Fund GmbH (BIVF) and Novo Seeds, and complemented by the High-Tech Gruenderfonds and coparion.
HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases, discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. In the healthy liver, hepatocytes have a near endless capacity to regenerate. However, in liver diseases, this regenerative capacity is locked and excessive hepatocyte death cannot be compensated, ultimately leading to loss of liver function and often death.
Click here to read the full press release.
Copenhagen, Denmark – December 28, 2016
IO Biotech today announced successful closure of the €8.5 million second tranche series A investment round. Participants were existing investors Lundbeckfonden and Novo Seeds plus new investor Sunstone Capital.
Click here to read IO Biotech's news release.